Neonates with CNS candidiasis have been reported to have a poor neurological outcome, making accurate diagnosis and appropriate therapy of paramount importance. 9, 10 There are limited reports in the literature of brain imaging of very low birth weight (VLBW) infants with CNS Candida infection. [11] [12] [13] We present three cases of VLBW infants with Candida albicans fungemia who had brain microabscesses (<3 mm) detected by head ultrasound (HUS) and magnetic resonance imaging (MRI) who were successfully treated with prolonged therapy.
Case no. 1 A 26-week gestational age 790-gram female infant was born to a 24-year-old woman. Blood cultures were negative; however, she received 7 days of ampicillin and gentamicin.
On day of life (DOL) 19, she developed temperature instability and pustules on her legs and wrist; complete blood count revealed a white blood cell (WBC) of 42.7 Â 10 9 per liter and platelets of 137 Â 10 9 per liter. Blood, urine and pustule cultures grew C. albicans and amphotericin B deoxycholate was started. On the first day of candidemia, HUS showed no signs of fungal infection. Cerebral spinal fluid (CSF) analysis showed 1625 Â 10 9 per liter red blood cells (RBC), 195 Â 10 9 per liter WBC with 68% neutrophils, 13% lymphocytes and 18% monocytes, protein of 245 mg per 100 ml and glucose of 46 mg per 100 ml. Cerebrospinal fluid (CSF) Gram stain and cultures, obtained after one dose of amphotericin B deoxycholate, were negative. An HUS obtained 3 days after first positive blood culture revealed multiple, scattered, ill-defined, echogenic parenchymal lesions bilaterally (Figure 1a) . Flucytosine was added. An MRI obtained 7 days after first positive culture showed numerous enhancing parenchymal lesions throughout the supratentorial and infratentorial brain (Figure 1b) . Evaluation for additional end organ damage was performed ( Table 1 ). The infant improved with treatment. Repeat imaging obtained at regular intervals showed persistent but less prominent echogenic lesions, with complete resolution of parenchymal lesions noted 6 months after first positive blood culture. Follow-up at 18 and 24 months revealed a developmentally normal toddler.
Case no. 2 A 28-week gestational age 1075-gram male infant was born to a 40 year-old woman. He was treated with 7 days of ampicillin and gentamicin in the first week of life because of apnea and bradycardia.
On DOL 16, because of recurrent apnea and bradycardia, blood cultures were sent and ampicillin and gentamicin were restarted. Complete blood count revealed a WBC count of 7 Â 10 9 per liter and platelets of 135 Â 10 9 per liter. Blood culture grew C. albicans. A lumbar puncture (LP) was carried out; the CSF was bloody, the Gram stain was negative and the culture grew C. albicans. Amphotericin B deoxycholate was started immediately following the LP. An HUS performed 2 days after the first positive blood culture showed no signs of CNS involvement. After 1 day of amphotericin B deoxycholate, a repeat LP was performed, revealing 1500 Â 10 9 per liter RBC, 103 Â 10 9 per liter WBC with 59% neutrophils, 18% lymphocytes and 23% monocytes, protein of 67 mg per 100 ml and glucose of 110 mg per 100 ml. CSF culture was again positive for C. albicans. Flucytosine was added. At 8 days after the first positive blood culture, repeat HUS revealed multiple echogenic foci seen throughout both cerebral hemispheres and within the ventricles (Figure 2a ). An MRI obtained 2 weeks after first positive culture revealed multiple punctuate foci with marked enhancement and reduced diffusion within both cerebral hemispheres (Figure 2b ). Imaging was obtained for follow-up at regular intervals showing less prominent foci and a reduction in the number of lesions. Complete resolution of all echogenic foci was reported 5 months after the first positive blood culture. Followup at 6 and 18 months revealed a developmentally normal child.
Case no. 3 A 28-week gestational age 1080-gram female infant was born to a 30-year-old woman. She received 7 days of ampicillin and gentamicin. At the end of her second week of life, she developed Staphylococcus epidermidis bacteremia and was treated with 7 days of vancomycin. On DOL 21, the infant developed a candidal diaper rash, treated with topical nystatin. Three days later, she developed apnea and bradycardia. A septic work-up was carried out that showed a WBC count of 8.8 Â 10 9 per liter, platelets of 232 Â 10 9 per liter and positive blood culture for C. albicans. An LP was attempted unsuccessfully. After receiving ampicillin, gentamicin and amphotericin B deoxycholate, she began to improve. Three days after the first positive blood culture, an HUS showed no signs of CNS infection. Four days after the first positive (Figure 3a) . MRI of the head obtained 9 days after first positive blood culture revealed multifocal punctuate enhancement in the subtentorial, subcortical and periventricular white matter (Figure 3b ). The infant improved on therapy. Follow-up imaging showed smaller and more distinct echogenic foci that persisted in subsequent ultrasounds. Resolution of microabscesses was noted 4 months after the first positive blood culture. Follow-up at 18 and 24 months of age, revealed a developmentally normal child.
All infants received 3 weeks of amphotericin B deoxycholate (1 mg per kg per day), followed by oral fluconazole (12 mg per kg per day) for 3 months. The oral flucytosine (100 mg per kg per day) was administered for 6 weeks. All infants tolerated the medications well. 
Discussion
Candida infection of the CNS has been known to result in poor outcome. In an older series, Chesney reports 29% mortality and hydrocephalus or developmental delay as common sequelae of Candida meningitis in infants.
14 More recently, perhaps because of earlier recognition or improved therapy, outcomes have been more favorable.
In this series, three infants accrued over a 4-month period were diagnosed with multiple brain microabscesses associated with Candida infection. No antifungal prophylaxis was being used at the time in the NICU. These infants were identified early based on high clinical suspicion and therapy was started immediately. Because of the abnormal cranial ultrasound suggestive of CNS Candida microabscesses, therapy was continued for 3 months.
In this case series, both ultrasound and MRI detected microabscesses equally. Imaging changes consistent with Candida CNS involvement were not seen in the first days of candidemia, but were apparent in all cases 1 week into the course. Resolution of parenchymal echogenic foci also lagged behind the clinical response and persisted even after completion of treatment.
In addition to an LP, it may be prudent to include CNS imaging with ultrasound and to repeat the study if the initial evaluation is normal, as late changes were present in each of these patients. We did not find that the increased detail seen on MRI was more sensitive than cranial ultrasound or that it influenced clinical care, though there may be a role for MRI in ultrasound negative patients. It is our opinion that ultrasound should be the preferred initial imaging method to evaluate CNS involvement in the neonate, given its portability, lack of required sedation, avoidance of radiation and ease of follow-up. Given the need for more prolonged antifungal therapy if there is CNS involvement, we believe it is important to aggressively pursue the possibility of CNS disease in candidemic infants. Further studies are needed to evaluate length of therapy, optimal imaging modality and optimal time to image after the first positive blood culture is documented.
